Skip to main content
PMC home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1996 May;73(10):1265–1267. doi: 10.1038/bjc.1996.242

Phase II study of a short course of weekly high-dose cisplatin combined with long-term oral etoposide in metastatic colorectal cancer.

A S Planting 1, M E van der Burg 1, M J van den Bent 1, M de Boer-Dennert 1, G Stoter 1, J Verweij 1
PMCID: PMC2074526  PMID: 8630290

Abstract

In a phase I study of weekly administered cisplatin combined with oral etoposide, we observed a partial response in 4 out of 11 patients with metastatic colorectal cancer. Subsequently, we performed a phase II study to investigate the activity of this combination as first-line treatment in this disease. Fourteen patients with metastatic colorectal cancer were enrolled in this study. Treatment consisted of cisplatin, administered in 3% sodium chloride, at a dose of 70 mg m-2 on days 1, 8 and 15 and days 29, 36 and 43 combined with oral etoposide 50 mg absolute dose daily on days 1-15 of both courses. Patients with stable disease or better continued treatment with etoposide 50 mg m-2 orally on days 1-21 every 28 days. A partial response was observed in two patients with liver metastases (14%; 95% confidence limits 2-42%) for 30 and 32 weeks. Five patients had stable disease. Toxicity consisted mainly of anaemia, leucocytopenia, nausea and vomiting. Tinnitus was reported by six patients. The activity of the combination cisplatin-oral etoposide in the schedule is only minimal in metastatic colorectal cancer.

Full text

PDF
1265

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. DeSimone P. A., Davila E., Jochimsen P. R., Bartolucci A. A. High-dose cisplatin in the treatment of advanced adenocarcinoma of the colon and rectum: a Southeastern Cancer Study Group trial. Cancer Treat Rep. 1986 Oct;70(10):1229–1230. [PubMed] [Google Scholar]
  2. Douglass H. O., Jr, Lavin P. T., Evans J. T., Mittelman A., Carbone P. P. Phase II evaluation of diglycoaldehyde, VP-16-213, and the combination of methyl-CCNU and beta-2'-deoxythioguanosine in previously treated patients with colorectal cancer: an Eastern Cooperative Oncology Group study (EST-1275). Cancer Treat Rep. 1979 Aug;63(8):1355–1357. [PubMed] [Google Scholar]
  3. Greco F. A., Johnson D. H., Hainsworth J. D. Chronic daily administration of oral etoposide. Semin Oncol. 1990 Feb;17(1 Suppl 2):71–74. [PubMed] [Google Scholar]
  4. Kemeny N., Israel K., Niedzwiecki D., Chapman D., Botet J., Minsky B., Vinciguerra V., Rosenbluth R., Bosselli B., Cochran C. Randomized study of continuous infusion fluorouracil versus fluorouracil plus cisplatin in patients with metastatic colorectal cancer. J Clin Oncol. 1990 Feb;8(2):313–318. doi: 10.1200/JCO.1990.8.2.313. [DOI] [PubMed] [Google Scholar]
  5. Labianca R., Pancera G., Cesana B., Clerici M., Montinari F., Luporini G. Cisplatin + 5-fluorouracil versus 5-fluorouracil alone in advanced colorectal cancer: a randomized study. Eur J Cancer Clin Oncol. 1988 Oct;24(10):1579–1581. doi: 10.1016/0277-5379(88)90048-x. [DOI] [PubMed] [Google Scholar]
  6. LoRusso P., Pazdur R., Redman B. G., Kinzie J., Vaitkevicius V. Low-dose continuous infusion 5-fluorouracil and cisplatin: phase II evaluation in advanced colorectal carcinoma. Am J Clin Oncol. 1989 Dec;12(6):486–490. doi: 10.1097/00000421-198912000-00005. [DOI] [PubMed] [Google Scholar]
  7. Loehrer P. J., Sr, Turner S., Kubilis P., Hui S., Correa J., Ansari R., Stephens D., Woodburn R., Meyer S. A prospective randomized trial of fluorouracil versus fluorouracil plus cisplatin in the treatment of metastatic colorectal cancer: a Hoosier Oncology Group trial. J Clin Oncol. 1988 Apr;6(4):642–648. doi: 10.1200/JCO.1988.6.4.642. [DOI] [PubMed] [Google Scholar]
  8. Lokich J. J., Ahlgren J. D., Cantrell J., Heim W. J., Wampler G. L., Gullo J. J., Fryer J. G., Alt D. E. A prospective randomized comparison of protracted infusional 5-fluorouracil with or without weekly bolus cisplatin in metastatic colorectal carcinoma. A Mid-Atlantic Oncology Program study. Cancer. 1991 Jan 1;67(1):14–19. doi: 10.1002/1097-0142(19910101)67:1<14::aid-cncr2820670104>3.0.co;2-m. [DOI] [PubMed] [Google Scholar]
  9. Moertel C. G. Chemotherapy for colorectal cancer. N Engl J Med. 1994 Apr 21;330(16):1136–1142. doi: 10.1056/NEJM199404213301608. [DOI] [PubMed] [Google Scholar]
  10. Passalacqua R., Bisagni G., Cocconi G., Boni C., Di Blasio B., Ceci G. Cisplatin and etoposide in advanced colorectal carcinoma. Ann Oncol. 1991 Oct;2(9):687–688. doi: 10.1093/oxfordjournals.annonc.a058050. [DOI] [PubMed] [Google Scholar]
  11. Perry M. C., Moertel C. G., Schutt A. J., Reitemeier R. J., Hahn R. G. Phase II studies of dianhydrogalactitol and VP-16-213 in colorectal cancer. Cancer Treat Rep. 1976 Sep;60(9):1247–1250. [PubMed] [Google Scholar]
  12. Planting A. S., van der Burg M. E., de Boer-Dennert M., Stoter G., Verweij J. Phase I study of weekly high-dose cisplatin combined with long-term oral etoposide in advanced solid tumors. Ann Oncol. 1995 Feb;6(2):190–192. doi: 10.1093/oxfordjournals.annonc.a059117. [DOI] [PubMed] [Google Scholar]
  13. Posner M. R., Belliveau J. F., Weitberg A. B., Sabbath K., Wiemann M. C., Cummings F. J., Calabresi P. Continuous-infusion cisplatin and bolus 5-fluorouracil in colorectal carcinoma. Cancer Treat Rep. 1987 Oct;71(10):975–977. [PubMed] [Google Scholar]
  14. Scheithauer W., Depisch D., Kornek G., Pidlich J., Rosen H., Karall M., Prochaska M., Ernst A., Sebesta C., Eckhardt S. Randomized comparison of fluorouracil and leucovorin therapy versus fluorouracil, leucovorin, and cisplatin therapy in patients with advanced colorectal cancer. Cancer. 1994 Mar 15;73(6):1562–1568. doi: 10.1002/1097-0142(19940315)73:6<1562::aid-cncr2820730606>3.0.co;2-2. [DOI] [PubMed] [Google Scholar]
  15. Zaniboni A., Labianca R., Pancera G., Barni S., Frontini L., Marini G., Luporini G. Oral etoposide as second-line chemotherapy for colorectal cancer: a GISCAD study. Gruppo Italiano Studio Carcinomi Apparato Digerente. J Chemother. 1995 Jun;7(3):246–248. doi: 10.1179/joc.1995.7.3.246. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES